Spotter · Intent-Driven · Evidence-Backed

Ask one question. BioSniper reads the biotech company for you.

Spotter reads your intent, picks the right Agents, pulls evidence from 7 sources, and hands back a cited summary, risks, and next steps.

SECFDACT.govPubMedPatentsNewsMarket

Tell Spotter what to verify.

One line in — Spotter orchestrates the Agents and returns cited judgments.

Auto-Extract

Spotter reads SEC & FDA filings for you

Never Miss

PDUFA dates & catalyst tracking

Evidence-Based

Cross-verified with citations

7 Sources · 24/7

1,000+ companies tracked

Biotech Pulse

Live market · upcoming catalysts · curated insights — all at a glance.

XBI

$126.01-1.30%

IBB

$163.64-0.24%

New Trials Initiated

3,682

FDA Approvals

283

Partnership Deals

18,393

Phase 3 Completion

31%

1,620 Companies19,180 Trials53,035 SEC Filings54,009 PubMedUpdated 5/21/2026

Recent M&A

2026-05-18licensing: IMPAVIDO (miltefosine) oral capsules - Eton Pharmaceuticals entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO (miltefosine) oral capsules.
2026-05-14licensing: CT-202 - Amendment to license agreement making rights to CT-202 irrevocable, royalty-free, fully paid-up, and non-terminable, while eliminating future milestone and royalty obligations.
2026-05-13acquisition: Assertio Holdings, Inc. - Acquisition of Assertio Holdings, Inc. by Zydus Worldwide DMCC through a cash tender offer of $23.50 per share, followed by a merger.

Upcoming Catalysts

May 22
Phase3 Topline
TKPHFPhase 3 Topline: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intrave
May 22
Phase3 Topline
AZNPhase 3 Topline: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controll
May 25
Phase3 Topline
GTBPPhase 3 Topline: A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy
May 26
Phase3 Topline
GTBPPhase 3 Topline: A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate t
May 26
Phase3 Topline
AZNPhase 3 Topline: An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients Wi
May 28
Phase3 Topline
GLAXFPhase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
May 28
Phase3 Topline
DSGNPhase 3 Topline: Explore the Relationship Between Single Nucleotide Polymorphisms and Abiraterone Response and Toxici
May 28
Phase3 Topline
AZNPhase 3 Topline: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controll
View Full Calendar
Upgrade for full details